Antengene Corporation Limited (6996.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jay Mei M.D., Ph.D.
|
Founder, Chairman & CEO | 14.17M | -- | 1965 |
|
Mr. Yiteng Liu M.Sc.
|
Chief Operating Officer | -- | -- | 1985 |
|
Mr. Thomas Karalis B.Sc.
|
Corporate VP & Head of Asia Pacific Region | -- | -- | -- |
|
Ms. Rui Guo
|
Chief Business Officer | -- | -- | -- |
|
Dr. Hou Bing Ph.D.
|
Chief Scientific Officer & Executive Director | -- | -- | 1984 |
|
Ms. Shimin Sun M.D., M.P.H.
|
Corporate VP and Head of Clinical Enabling Functions & Operational Excellence | -- | -- | -- |
|
Dr. Dirk Hoenemann
|
VP and Head of Medical Affairs for APAC & Early Clinical Development | -- | -- | -- |
|
Ms. Ying Liu
|
Joint Company Secretary | -- | -- | -- |
Antengene Corporation Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 122
Description
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company's pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
